This research report provides a comprehensive analysis of the RNA-Based Therapeutics and Vaccines market, focusing on the current trends, market dynamics, and future prospects. The report explores the global RNA-Based Therapeutics and Vaccines market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of RNA-Based Therapeutics and Vaccines, challenges faced by the industry, and potential opportunities for market players.
The global RNA-Based Therapeutics and Vaccines market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The RNA-Based Therapeutics and Vaccines market presents opportunities for various stakeholders, including Oncology, Immunology. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in RNA-Based Therapeutics and Vaccines market. Additionally, the growing consumer demand present avenues for market expansion.
The global RNA-Based Therapeutics and Vaccines market was valued at US$ 24 million in 2023 and is projected to reach US$ 672.8 million by 2030, at a CAGR of 60.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the RNA-Based Therapeutics and Vaccines market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the RNA-Based Therapeutics and Vaccines market.
Market Overview: The report provides a comprehensive overview of the RNA-Based Therapeutics and Vaccines market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., RNA-Based Therapeutics, RNA-Based Vaccines), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the RNA-Based Therapeutics and Vaccines market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the RNA-Based Therapeutics and Vaccines market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the RNA-Based Therapeutics and Vaccines market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the RNA-Based Therapeutics and Vaccines market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the RNA-Based Therapeutics and Vaccines market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the RNA-Based Therapeutics and Vaccines market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for RNA-Based Therapeutics and Vaccines, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the RNA-Based Therapeutics and Vaccines market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
RNA-Based Therapeutics and Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
RNA-Based Therapeutics
RNA-Based Vaccines
Market segment by Application
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Outline of Major Chapters:
Chapter 1: Introduces the definition of RNA-Based Therapeutics and Vaccines, market overview.
Chapter 2: Global RNA-Based Therapeutics and Vaccines market size in revenue.
Chapter 3: Detailed analysis of RNA-Based Therapeutics and Vaccines company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of RNA-Based Therapeutics and Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 RNA-Based Therapeutics and Vaccines Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global RNA-Based Therapeutics and Vaccines Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global RNA-Based Therapeutics and Vaccines Overall Market Size
2.1 Global RNA-Based Therapeutics and Vaccines Market Size: 2023 VS 2030
2.2 Global RNA-Based Therapeutics and Vaccines Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top RNA-Based Therapeutics and Vaccines Players in Global Market
3.2 Top Global RNA-Based Therapeutics and Vaccines Companies Ranked by Revenue
3.3 Global RNA-Based Therapeutics and Vaccines Revenue by Companies
3.4 Top 3 and Top 5 RNA-Based Therapeutics and Vaccines Companies in Global Market, by Revenue in 2023
3.5 Global Companies RNA-Based Therapeutics and Vaccines Product Type
3.6 Tier 1, Tier 2 and Tier 3 RNA-Based Therapeutics and Vaccines Players in Global Market
3.6.1 List of Global Tier 1 RNA-Based Therapeutics and Vaccines Companies
3.6.2 List of Global Tier 2 and Tier 3 RNA-Based Therapeutics and Vaccines Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global RNA-Based Therapeutics and Vaccines Market Size Markets, 2023 & 2030
4.1.2 RNA-Based Therapeutics
4.1.3 RNA-Based Vaccines
4.2 By Type - Global RNA-Based Therapeutics and Vaccines Revenue & Forecasts
4.2.1 By Type - Global RNA-Based Therapeutics and Vaccines Revenue, 2019-2024
4.2.2 By Type - Global RNA-Based Therapeutics and Vaccines Revenue, 2025-2030
4.2.3 By Type - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global RNA-Based Therapeutics and Vaccines Market Size, 2023 & 2030
5.1.2 Oncology
5.1.3 Immunology
5.1.4 Ophthalmology
5.1.5 Cardiovascular Diseases
5.1.6 Infectious Diseases
5.1.7 Genetic Diseases
5.1.8 Others
5.2 By Application - Global RNA-Based Therapeutics and Vaccines Revenue & Forecasts
5.2.1 By Application - Global RNA-Based Therapeutics and Vaccines Revenue, 2019-2024
5.2.2 By Application - Global RNA-Based Therapeutics and Vaccines Revenue, 2025-2030
5.2.3 By Application - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global RNA-Based Therapeutics and Vaccines Market Size, 2023 & 2030
6.2 By Region - Global RNA-Based Therapeutics and Vaccines Revenue & Forecasts
6.2.1 By Region - Global RNA-Based Therapeutics and Vaccines Revenue, 2019-2024
6.2.2 By Region - Global RNA-Based Therapeutics and Vaccines Revenue, 2025-2030
6.2.3 By Region - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America RNA-Based Therapeutics and Vaccines Revenue, 2019-2030
6.3.2 US RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.3.3 Canada RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.3.4 Mexico RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe RNA-Based Therapeutics and Vaccines Revenue, 2019-2030
6.4.2 Germany RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4.3 France RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4.4 U.K. RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4.5 Italy RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4.6 Russia RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4.7 Nordic Countries RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.4.8 Benelux RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia RNA-Based Therapeutics and Vaccines Revenue, 2019-2030
6.5.2 China RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.5.3 Japan RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.5.4 South Korea RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.5.5 Southeast Asia RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.5.6 India RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America RNA-Based Therapeutics and Vaccines Revenue, 2019-2030
6.6.2 Brazil RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.6.3 Argentina RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue, 2019-2030
6.7.2 Turkey RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.7.3 Israel RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.7.4 Saudi Arabia RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
6.7.5 UAE RNA-Based Therapeutics and Vaccines Market Size, 2019-2030
7 RNA-Based Therapeutics and Vaccines Companies Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Company Summary
7.1.2 Alnylam Pharmaceuticals Business Overview
7.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Major Product Offerings
7.1.4 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.1.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.2 Arbutus Biopharma
7.2.1 Arbutus Biopharma Company Summary
7.2.2 Arbutus Biopharma Business Overview
7.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Major Product Offerings
7.2.4 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.2.5 Arbutus Biopharma Key News & Latest Developments
7.3 Arrowhead Pharmaceuticals
7.3.1 Arrowhead Pharmaceuticals Company Summary
7.3.2 Arrowhead Pharmaceuticals Business Overview
7.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Major Product Offerings
7.3.4 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.3.5 Arrowhead Pharmaceuticals Key News & Latest Developments
7.4 BioNTech
7.4.1 BioNTech Company Summary
7.4.2 BioNTech Business Overview
7.4.3 BioNTech RNA-Based Therapeutics and Vaccines Major Product Offerings
7.4.4 BioNTech RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.4.5 BioNTech Key News & Latest Developments
7.5 CureVac
7.5.1 CureVac Company Summary
7.5.2 CureVac Business Overview
7.5.3 CureVac RNA-Based Therapeutics and Vaccines Major Product Offerings
7.5.4 CureVac RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.5.5 CureVac Key News & Latest Developments
7.6 Dicerna Pharmaceuticals
7.6.1 Dicerna Pharmaceuticals Company Summary
7.6.2 Dicerna Pharmaceuticals Business Overview
7.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Major Product Offerings
7.6.4 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.6.5 Dicerna Pharmaceuticals Key News & Latest Developments
7.7 Regulus Therapeutics
7.7.1 Regulus Therapeutics Company Summary
7.7.2 Regulus Therapeutics Business Overview
7.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Major Product Offerings
7.7.4 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.7.5 Regulus Therapeutics Key News & Latest Developments
7.8 Marina Biotech
7.8.1 Marina Biotech Company Summary
7.8.2 Marina Biotech Business Overview
7.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Major Product Offerings
7.8.4 Marina Biotech RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.8.5 Marina Biotech Key News & Latest Developments
7.9 MiRagen Therapeutics
7.9.1 MiRagen Therapeutics Company Summary
7.9.2 MiRagen Therapeutics Business Overview
7.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Major Product Offerings
7.9.4 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.9.5 MiRagen Therapeutics Key News & Latest Developments
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Company Summary
7.10.2 Moderna Therapeutics Business Overview
7.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Major Product Offerings
7.10.4 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.10.5 Moderna Therapeutics Key News & Latest Developments
7.11 Quark Pharmaceuticals
7.11.1 Quark Pharmaceuticals Company Summary
7.11.2 Quark Pharmaceuticals Business Overview
7.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Major Product Offerings
7.11.4 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.11.5 Quark Pharmaceuticals Key News & Latest Developments
7.12 Roche
7.12.1 Roche Company Summary
7.12.2 Roche Business Overview
7.12.3 Roche RNA-Based Therapeutics and Vaccines Major Product Offerings
7.12.4 Roche RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.12.5 Roche Key News & Latest Developments
7.13 Sylentis
7.13.1 Sylentis Company Summary
7.13.2 Sylentis Business Overview
7.13.3 Sylentis RNA-Based Therapeutics and Vaccines Major Product Offerings
7.13.4 Sylentis RNA-Based Therapeutics and Vaccines Revenue in Global Market (2019-2024)
7.13.5 Sylentis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. RNA-Based Therapeutics and Vaccines Market Opportunities & Trends in Global Market
Table 2. RNA-Based Therapeutics and Vaccines Market Drivers in Global Market
Table 3. RNA-Based Therapeutics and Vaccines Market Restraints in Global Market
Table 4. Key Players of RNA-Based Therapeutics and Vaccines in Global Market
Table 5. Top RNA-Based Therapeutics and Vaccines Players in Global Market, Ranking by Revenue (2023)
Table 6. Global RNA-Based Therapeutics and Vaccines Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global RNA-Based Therapeutics and Vaccines Revenue Share by Companies, 2019-2024
Table 8. Global Companies RNA-Based Therapeutics and Vaccines Product Type
Table 9. List of Global Tier 1 RNA-Based Therapeutics and Vaccines Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 RNA-Based Therapeutics and Vaccines Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - RNA-Based Therapeutics and Vaccines Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - RNA-Based Therapeutics and Vaccines Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - RNA-Based Therapeutics and Vaccines Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - RNA-Based Therapeutics and Vaccines Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global RNA-Based Therapeutics and Vaccines Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global RNA-Based Therapeutics and Vaccines Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2025-2030
Table 30. Alnylam Pharmaceuticals Company Summary
Table 31. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Offerings
Table 32. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 33. Alnylam Pharmaceuticals Key News & Latest Developments
Table 34. Arbutus Biopharma Company Summary
Table 35. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Offerings
Table 36. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 37. Arbutus Biopharma Key News & Latest Developments
Table 38. Arrowhead Pharmaceuticals Company Summary
Table 39. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Offerings
Table 40. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 41. Arrowhead Pharmaceuticals Key News & Latest Developments
Table 42. BioNTech Company Summary
Table 43. BioNTech RNA-Based Therapeutics and Vaccines Product Offerings
Table 44. BioNTech RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 45. BioNTech Key News & Latest Developments
Table 46. CureVac Company Summary
Table 47. CureVac RNA-Based Therapeutics and Vaccines Product Offerings
Table 48. CureVac RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 49. CureVac Key News & Latest Developments
Table 50. Dicerna Pharmaceuticals Company Summary
Table 51. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Offerings
Table 52. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 53. Dicerna Pharmaceuticals Key News & Latest Developments
Table 54. Regulus Therapeutics Company Summary
Table 55. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Offerings
Table 56. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 57. Regulus Therapeutics Key News & Latest Developments
Table 58. Marina Biotech Company Summary
Table 59. Marina Biotech RNA-Based Therapeutics and Vaccines Product Offerings
Table 60. Marina Biotech RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 61. Marina Biotech Key News & Latest Developments
Table 62. MiRagen Therapeutics Company Summary
Table 63. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Offerings
Table 64. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 65. MiRagen Therapeutics Key News & Latest Developments
Table 66. Moderna Therapeutics Company Summary
Table 67. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Offerings
Table 68. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 69. Moderna Therapeutics Key News & Latest Developments
Table 70. Quark Pharmaceuticals Company Summary
Table 71. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Offerings
Table 72. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 73. Quark Pharmaceuticals Key News & Latest Developments
Table 74. Roche Company Summary
Table 75. Roche RNA-Based Therapeutics and Vaccines Product Offerings
Table 76. Roche RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 77. Roche Key News & Latest Developments
Table 78. Sylentis Company Summary
Table 79. Sylentis RNA-Based Therapeutics and Vaccines Product Offerings
Table 80. Sylentis RNA-Based Therapeutics and Vaccines Revenue (US$, Mn) & (2019-2024)
Table 81. Sylentis Key News & Latest Developments
List of Figures
Figure 1. RNA-Based Therapeutics and Vaccines Segment by Type in 2023
Figure 2. RNA-Based Therapeutics and Vaccines Segment by Application in 2023
Figure 3. Global RNA-Based Therapeutics and Vaccines Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global RNA-Based Therapeutics and Vaccines Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global RNA-Based Therapeutics and Vaccines Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by RNA-Based Therapeutics and Vaccines Revenue in 2023
Figure 8. By Type - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 9. By Application - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 10. By Type - Global RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 12. By Application - Global RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 14. By Region - Global RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 15. By Country - North America RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 16. US RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 17. Canada RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 20. Germany RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 21. France RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 23. Italy RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 24. Russia RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 28. China RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 29. Japan RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 32. India RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 34. Brazil RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue Market Share, 2019-2030
Figure 37. Turkey RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 38. Israel RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 40. UAE RNA-Based Therapeutics and Vaccines Revenue, (US$, Mn), 2019-2030
Figure 41. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. BioNTech RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. CureVac RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Marina Biotech RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Roche RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Sylentis RNA-Based Therapeutics and Vaccines Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
